Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines

Breast Cancer

Volumn 22, Issue 4, 2015, Pages 382-390

  Taghizadeh, Bita ^a   Ghavami, Laleh ^a   Nikoofar, Alireza ^b   Goliaei, Bahram ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Breast cancer; Comet assay; Equol; Radiosensitizer

Indexed keywords

EQUOL; ESTROGEN RECEPTOR; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC50; IRRADIATION; PRIORITY JOURNAL; RADIOSENSITIVITY; BREAST NEOPLASMS; DNA DAMAGE; DRUG EFFECTS; FEMALE; METABOLISM; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; EQUOL; FEMALE; HUMANS; RADIATION-SENSITIZING AGENTS; RECEPTORS, ESTROGEN;

EID: 84933180656     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-013-0492-0     Document Type: Article

References (55)

1. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43.
2. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006;66(7):3347–50.
3. Vallerga AK, Zarling DA, Kinsella TJ. New radiosensitizing regimens, drugs, prodrugs, and candidates. Clin Adv Hematol Oncol. 2004;2(12):793–805.
4. Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal. 2005;7(11–12):1630–47.
5. Romieu I. Diet and breast cancer. Salud Publica Mex. 2011;53(5):430–9.
6. Michels KB, et al. Diet and breast cancer: a review of the prospective observational studies. Cancer. 2007;109(12 Suppl):2712–49.
7. Clavel-Chapelon F, Niravong M, Joseph RR. Diet and breast cancer: review of the epidemiologic literature. Cancer Detect Prev. 1997;21(5):426–40.
8. Giovannucci E. Nutritional factors in human cancers. Adv Exp Med Biol. 1999;472:29–42.
9. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999; 49(1): 33–64, 1.
10. Ziegler RG, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993;85(22):1819–27.
11. Dai Q, et al. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer. 2001;85(3):372–8.
12. Wu AH, et al. Soy intake and risk of breast cancer in Asians and Asian Americans. Am J Clin Nutr. 1998;68(6 Suppl):1437S–43S.
13. Messina MJ, et al. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 1994;21(2):113–31.
14. Cassidy A. Physiological effects of phyto-oestrogens in relation to cancer and other human health risks. Proc Nutr Soc. 1996;55(1B):399–417.
15. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst. 2006;98(18):1275–84.
16. Reinli K, Block G. Phytoestrogen content of foods—a compendium of literature values. Nutr Cancer. 1996;26(2):123–48.
17. Dixon RA. Phytoestrogens. Annu Rev Plant Biol. 2004;55:225–61.
18. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr. 1998;68(6 Suppl):1333S–46S.
19. Setchell KD, et al. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr. 1984;40(3):569–78.
20. Woclawek-Potocka I, et al. Phytoestrogen metabolites are much more active than phytoestrogens themselves in increasing prostaglandin F(2alpha) synthesis via prostaglanin F(2alpha) synthase-like 2 stimulation in bovine endometrium. Prostaglandins Other Lipid Mediat. 2005;78(1–4):202–17.
21. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood). 2005;230(3):155–70.
22. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132(12):3577–84.
23. Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr. 2010;140(7):1355S–62S.
24. Axelson MS, Setchell KD. The excretion of lignans in rats—evidence for an intestinal bacterial source for this new group of compounds. FEBS Lett. 1981;123:337–42.
25. Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA. The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med. 1995;208:40–3.
26. Karr SC, Lampe JW, Hutchins AM, Slavin JL. Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. Am J Clin Nutr. 1997;66:46–51.
27. Lampe JW, Karr SC, Hutchins AM, Slavin JL. Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med. 1998;217:335–9.
28. Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut flora. Nutr Cancer. 2000;36:27–32.
29. Shi J, et al. Equol induced apoptosis of human breast cancer MDA-MB-231 cell by inhibiting the expression of nuclear factor-kappaB. Wei Sheng Yan Jiu. 2011;40(1):95–8.
30. Choi EJ, Ahn WS, Bae SM. Equol induces apoptosis through cytochrome c-mediated caspases cascade in human breast cancer MDA-MB-453 cells. Chem Biol Interact. 2009;177:7–11.
31. Lau TY, Leung LK. Soya isoflavones suppress phorbol 12-myristate 13-acetate-induced COX-2 expression in MCF-7 cells. Br J Nutr. 2006;96:169–76.
32. Magee PJ, McGlynn H, Rowland IR. Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Lett. 2004;208:35–41.
33. Kang NJ, Lee KW, Rogozin EA. Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem. 2007;282:32856–66.
34. Gluz O, et al. Triple-negative breast cancer–current status and future directions. Ann Oncol. 2009;20(12):1913–27.
35. Takahashi Y, Lavigne JA, Hursting SD. Molecular signatures of soy-derived phytochemicals in androgen-responsive prostate cancer cells: a comparison study using DNA microarray. Mol Carcinog. 2006;45:943–56.
36. Yan L, Li D, Yee JA. Dietary supplementation with isolated soy protein reduces metastasis of mammary carcinoma cells in mice. Clin Exp Metastasis. 2002;19:535–40.
37. Hodgson JM, Croft KD, Puddey IB, Mori TA, Beilin LJ. Soybean isoflavonoids and their metabolic products inhibit in vitro lipoprotein oxidation in serum. J Nutr Biochem. 1991;7:664–9.
38. Collins AR, Duthie GG. Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem Biophys. 1998;360:142–8.
39. Arora A, Nair MG, Strasburg GM. Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch Biochem Biophys. 1998;256:133–41.
40. Reed, J.C., Apoptosis. Volume 322 of Methods in enzymology Methods in Enzymology S., v. 322, ed. J.C.R. John N. Abelson, Melvin I. Simon2000: Academic Press. 569.
41. Collins AR, et al. The comet assay: what can it really tell us? Mutat Res. 1997;375(2):183–93.
42. Singh NP, et al. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175(1):184–91.
43. Rakha EA, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32.
44. Cheang MC, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368–76.
45. Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.
46. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52(1):108–18.
47. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast. 2010;19(5):312–21.
48. Kyndi M, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(9):1419–26.
49. Charalambous C, Pitta CA, Constantinou AI. Equol enhances tamoxifen’s anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells. BMC Cancer. 2013;13:238.
50. Thomas C, et al. ERbeta1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res. 2012;14(6):R148.
51. Sarrio D, et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68(4):989–97.
52. Vladusic EA, et al. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol Rep. 2000;7(1):157–67.
53. Adams M, et al. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res. 2002;62(11):3289–97.
54. Bardin A, et al. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11(3):537–51.
55. Harris DM, et al. Phytoestrogens induce differential estrogen receptor alpha- or Beta-mediated responses in transfected breast cancer cells. Exp Biol Med (Maywood). 2005;230(8):558–68.